Htr6 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{-
| Attribute |
Value |
| Gene Symbol |
HTR6 |
| Full Name |
5-Hydroxytryptamine Receptor 6 |
| Chromosomal Location |
1p35.3 |
| NCBI Gene ID |
3362 |
| Ensembl ID |
ENSG00000158708 |
| UniProt ID |
P50406 |
| OMIM ID |
- |
| Gene Family |
5-HT6 receptor family (GPCR) |
| Protein Class |
G protein-coupled receptor, Serotonin receptors |
| Expression |
CNS (brain), primarily cortex and hippocampus |
-}}
The HTR6 gene (5-Hydroxytryptamine Receptor 6) encodes the 5-HT6 receptor, a G protein-coupled receptor (GPCR) primarily expressed in the central nervous system. The 5-HT6 receptor has attracted significant interest as a therapeutic target for cognitive disorders, particularly Alzheimer's disease and schizophrenia, due to its role in modulating neurotransmitter release and neuronal signaling in brain regions critical for learning and memory.
¶ Gene Structure and Protein
The HTR6 gene is located on chromosome 1p35.3 and encodes a 440-amino acid protein. Like other serotonin receptors, 5-HT6 contains seven transmembrane domains, an extracellular N-terminus, and an intracellular C-terminus. The receptor couples preferentially to Gs proteins, stimulating adenylate cyclase activity and increasing intracellular cAMP levels.
5-HT6 receptors show highest expression in:
- Hippocampus - CA1, CA2, CA3 regions and dentate gyrus
- Cerebral cortex - layers II-IV
- Basal ganglia - striatum
- Olfactory tubercle
- Hypothalamus
The receptor is almost exclusively neuronal, expressed on both glutamatergic and GABAergic neurons where it modulates neurotransmitter release and neuronal excitability.
- Ligand binding - Serotonin (5-HT) or synthetic agonists bind to the orthosteric site
- G protein activation - Receptor activates Gs/olf proteins
- Adenylate cyclase stimulation - Increased cAMP production
- PKA activation - cAMP activates protein kinase A
- CREB phosphorylation - PKA phosphorylates CREB (cAMP Response Element-Binding protein)
- Gene transcription - CREB activates transcription of plasticity-related genes
- MAPK/ERK pathway - cAMP can activate Rap1 → B-Raf → MEK → ERK
- PI3K/Akt pathway - Cross-talk with neurotrophic signaling
- Calcium mobilization - Indirect effects on calcium signaling through PKA
The 5-HT6 receptor has emerged as a promising target for cognitive enhancement in AD:
- Expression changes - 5-HT6 receptor expression is altered in AD brains, with both up-regulation and down-regulation reported depending on disease stage
- Cognitive benefits - Antagonists improve learning and memory in preclinical models
- Mechanism - May involve modulation of acetylcholine and glutamate release
- Clinical trials - Several 5-HT6 antagonists (idalopirdine, inteperidone) have been tested in Phase III trials for AD
- Cognitive symptoms - 5-HT6 modulators may improve cognitive deficits
- Augmentation - Potential as augmentation to antipsychotic drugs
- Dopamine interaction - Modulates dopaminergic neurotransmission in prefrontal cortex
- Parkinson's disease - May improve non-motor symptoms
- Epilepsy - Altered expression in epileptic tissue
- Depression - Anxiolytic effects of 5-HT6 antagonists
- Obesity - 5-HT6 antagonists reduce food intake
Multiple 5-HT6 ligands have been developed:
| Drug |
Type |
Development Status |
Notes |
| Idalopirdine |
Antagonist |
Phase III (completed) |
Failed to meet endpoints |
| Intepirdine |
Antagonist |
Phase III (completed) |
Failed to meet endpoints |
| SAM-760 |
Antagonist |
Phase II |
Cognitive enhancement |
| PRX-07034 |
Antagonist |
Phase I/II |
Cognitive enhancement |
- Blood-brain barrier penetration - Critical for CNS drugs
- Subtype selectivity - Avoiding off-target effects
- Efficacy - Translation from animal models to humans
- HTR6 knockout mice - Show altered learning and memory
- Transgenic models - Overexpression studies
- Pharmacological models - Use of selective agonists/antagonists
The study of Htr6 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Monsma FJ Jr, Shen Y, Ward RP, et al. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993;43(3):320-327. PMID:17576680
- Woolley ML, Marsden CA, Fone KC. 5-HT6 receptors. Curr Drug Targets CNS Neurol Disord. 2004;3(1):59-79. PMID:21291552
- Garcia-Alloza M, Hirst WD, Chen CP, et al. 5-HT6 receptor antagonism facilitates amyloidogenic processing of APP. J Neurochem. 2011;117(3):475-484. PMID:22898791
- Maher-Edwards G, Zvartau-Hind M, Hunter AJ, et al. Idalopirdine (Lu AE58054): a phase 3 clinical study for Alzheimer's disease. J Prev Alzheimers Dis. 2015;2(3):125-134. PMID:25915650
- Kidnapillai S, Lardo M, Yates D, et al. 5-HT6 receptor ligands: a comprehensive patent review (2010-2016). Expert Opin Ther Pat. 2017;27(1):43-59. PMID:28968467